Background: Desmoid tumours represent a major complication of familial adenomatous polyposis. Our aims were to study the factors associated with the development of desmoid tumours in familial adenomatous polyposis patients, and to describe presentation and management of desmoid tumours.
Introduction
Familial adenomatous polyposis (FAP) is a hereditary condition transmitted in an autosomal dominant fashion, which is characterised by the appearance of numerous adenomatous polyps in the colon and rectum. This condition results from germline mutation of the adenomatous polyposis coli (APC) gene on chromosome 5 and accounts for 1% of cases of colorectal cancer. 1 For patients with FAP, progression to colorectal cancer is inevitable and cancer occurs at an average age of 39 years, 2 which turns surgical treatment into the first and only choice of therapy.
Desmoid tumours (DTs), from the Greek word desmos (tendon-like), are benign monoclonal fibroblastic proliferations arising in musculoaponeurotic structures. 3 They do not metastasise but can display aggressive biological behaviour characterised by infiltrative growth and a high recurrence rate after resection. They are relatively rare lesions representing <3% of all soft tissue tumours with a reported annual incidence of 0.2-0.5 per 100,000 persons. [4] [5] [6] In contrast, the association of DTs and FAP is relatively frequent. According to Gurbuz et al., a patient with FAP is at a 852-fold increased risk of developing a DT compared with the general population. 7 The exact aetiology of DT development is not known, but several factors contribute to their development and growth, such as genetic predisposition, [8] [9] [10] [11] hormonal factors and trauma (i.e. surgery) 7,10,12-14 which may partially explain the high proportion of DTs in patients with FAP. There are currently no national or international guidelines for the management of DTs, and no recommended first-line systemic treatment. However, some DTs exhibit self-limiting behaviour and show growth arrest or spontaneous regression and, therefore, a wait-and-see approach seems to be an appropriate option for these selected patients. Otherwise, therapy consists of surgery, radiotherapy and/or systemic approaches in various non-standardised combinations. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Surgery is the main treatment strategy, but is associated with a high risk of recurrence and function loss especially for patients with mesenteric DT.
In this context, we therefore conducted a retrospective study to evaluate the frequency and risk factors associated with the development of DTs in FAP patients, describe presentation of DTs, and report outcomes after treatment of DTs.
Patients and methods

Patients with FAP
We retrospectively reviewed all FAP patients, identified from a national prospective database (clinical trial no.: NCT01987518), treated and regularly followed in our tertiary centre between 1965-2013. The medical records of all patients were reviewed carefully for data on demographics (age, sex, previous medical history), diagnosis and pattern of FAP lesions (number and stage of colorectal tumours, duodenal tumours), surgical procedure data (age at surgery, laparoscopy versus laparotomy, anastomosis type), pathology, complications and outcomes.
DTs
The diagnosis of DTs was done firstly by radiology, then confirmed by pathology for those who underwent surgery. No biopsy of DT was routinely recommended in this very specific situation of FAP. DT patients were divided into two groups according to tumour location: mesenteric DT and extra-mesenteric DT. Treatment was categorised as either surgery or systemic therapy or, if no treatment was received over the follow-up period, 'wait and see'. For patients who underwent surgery for DTs, recurrence and the time to recurrence or last known status is reported, and recurrence-free survival (RFS) was calculated (from DT surgery to the date of DT recurrence or death from any cause). Systemic treatments were only prescribed in cases of DT progression and/or symptomatic DT, and when surgery was not an option. Responses to systemic treatments were evaluated according to the Response Evaluation Criteria In Solid Tumor (RECIST) criteria, 25 as complete response (CR), partial regression (PR), stable disease (SD) and progressive disease (PD). Progression-free survival (PFS) was calculated from initiation of each systemic treatment to the date of disease progression according to RECIST criteria or death from any cause, whichever occurred first.
Statistics
Categorical variables were expressed as percentages, and compared by the Chi-square test or with Fisher's exact test. Unpaired parameters were calculated by means of t tests or analysis of variance (ANOVA) tests. Continuous variables were expressed as median with range. Occurrence of DT and survival curves (RFS and PFS) were assessed using Kaplan-Meier analysis. Results are given as median survival (95% confidence interval (CI)). A p value of <0.05 was considered statistically significant.
Results
Patient characteristics
Two hundred and twenty-nine patients were identified from the national prospective database. Among them, 190 patients had complete medical and surgical information and a genetic analysis performed for APC and/or MutY human homologue (MYH) germline mutation. Ten patients with identified bi-allelic MYH mutation, in whom no DT occurred, were excluded from the study. Therefore, 180 FAP patients with a known APC mutation (n ¼ 140) or who corresponded to the phenotype of APC-like FAP (n ¼ 40) were included in this study. At diagnosis, 76 (42%) were male and median (range) age 23 (11-65) years. All patients underwent a colonic AE rectum surgery, at a median age of 25 years (28 years for females and 25 years for males, p ¼ 0.05): for 176 (98%) patients, this was a prophylactic treatment, and four (2%; all female) patients were diagnosed with colorectal cancer before surgery. Seventy-seven (43%) patients had a laparoscopy and 103 (57%) patients a laparotomy. One hundred and four (58%) patients had a colectomy with rectal preservation, and 76 (42%) patients underwent a proctocolectomy ( Table 1) . One female patient developed a rectal cancer (pT3N0M0), six years after colectomy which justified a second surgery. The median (range) duration of follow-up from the time of FAP diagnosis to the last known status for the 180 FAP patients was 19 (1-48) years. Three patients died after diagnosis of FAP, from hepatic failure after embolisation of DT (five years after the diagnosis of FAP), metastatic colorectal cancer (eight years), and pancreatic cancer (32 years).
Frequency and risk factors of DTs in FAP patients
During follow-up, 31 (17%) patients with a FAP developed at least one DT, after a median (range) 4.7 (0.8-41.6) years after colonic AE rectum surgery. Of the 104 patients who underwent a colectomy with rectal preservation, 12 (11% of those concerned) patients developed a DT, as compared to 19/76 (25%) patients who underwent a proctocolectomy (p ¼ 0.027) ( Table  1) . Occurrence of DT in the 180 FAP patients over time, according to the type of surgical resection (colectomy versus proctocolectomy) is shown in Figure 1 . The prevalence of DTs was 12/104 (12%) in patients with ileorectal (IR) anastomosis, 13/61 (21%) in patients with ileoanal (IA) anastomosis, and 6/15 (40%) in patients with terminal ileostomy. (1-25) cm. There was no significant difference between genders for age at DT occurrence (31 years for females versus 36 years for males, p ¼ 0.37), mean number of DTs (1.6 for females versus 1.9 for males, p ¼ 0.45), and 1-7) . The efficacy of these treatments is summarised in Table 2 and Figure 3 . Systemic treatments was given to patients with progressive DT were celecoxib-sorafenib (n ¼ 2), celecoxib-imatinib (n ¼ 1), doxorubicin-ifosfamide (n ¼ 2), bevacizumab (n ¼ 2), imatinib (n ¼ 4), tamoxifen-imatinib (n ¼ 1), tamoxifen-celecoxib (n ¼ 1), tamoxifen-sulindac (n ¼ 3), tamoxifen (n ¼ 1), sulindac (n ¼ 4), or celecoxib (n ¼ 6). An objective response was observed in four (15%) cases, and stable disease in 21 (75%) of cases, without significant difference between mesenteric and extra-mesenteric DTs (p ¼ 0.51). Median (95% CI) PFS was 9.0 (1.1-16.9) months.
Presentation and management of DTs
Discussion
In the present study, the prevalence of DTs was 17%, but may be slightly underestimated owing to the short postoperative follow-up of some young patients. It does, however, concord with that reported in the literature (9-26%), with more recent publications reporting higher prevalence. When comparing the characteristics of FAP patients with and without DTs, there was no significant difference found in sex, age at FAP diagnosis, age at colonic surgery, APC mutation rate or surgical technique (laparotomy versus laparoscopy). However, the main observation of this retrospective study, was a significant difference between the extension of colon and rectum resection and further development of DTs: there was a significant two-fold higher probability of DT occurrence among patients who underwent proctocolectomy as compared to those who underwent sub-total colectomy. It is also of note that patients harbouring a definitive ileostomy and proctocolectomy had the highest prevalence of DTs. The physiological basis for this difference needs further investigation but one hypothesis may be that extensive surgery increases local inflammation and favours the inflammatory process leading to the development of DTs. Interestingly, there was no risk difference between patients with laparotomy versus laparoscopy. Because of study limitations (size of the population and retrospective analysis), larger studies are needed to confirm this result. We are now running a national French database register (clinical trial no.: NCT01987518) that could help answer this important question. However, given the improved ability of endoscopic aggressive follow-up of the rectal stump to decrease the risk of secondary proctectomy, 32 the lower functional results of proctocolectomy, 33 and the fertility issue in women, 34 this is a new argument in favour of simple colectomy in a majority of FAP patients.
The second part of the study aimed to describe the presentation and management of 58 DTs in 31 FAP patients. The median age at DT diagnosis in our study (33 years) was comparable as that reported in previous studies (31-34 years). 26, 28, 31 There was no difference between genders regarding the rate of DT occurrence. We also did not confirm the results reported by Schiessling et al. 26 showing a higher number of DTs per patient, and a larger total DT size in male patients. Treatment of DTs in FAP patients remains a difficult challenge, with poor progress in comparison with the prevention of colorectal and duodenal cancers that has highly improved over the last 20 years. Simple surveillance remains a recommendation in patients with stable and non-life-threatening disease, 35 but these represented only three of our 31 patients and they had a relatively short follow-up. The study found that surgery remains a major option in DT of FAP patients, but recurrences are frequent (nearly three-quarters of patients). Thus, the two options (extensive surgery or medical treatments) should be considered. Conclusions about medical systemic treatments of DT in FAP patients are difficult to make because of the wide range of treatments used. Several different regimens were used in this study, which were discussed in multidisciplinary tumour board specialised in sarcoma. Most of these drugs (tamoxifen, non-steroidal anti-inflammatory drugs, sorafenib, imatinib) are reported alone or in combination in European Society for Medical Oncology (ESMO) guidelines. 3 Bevacizumab is not listed in these guidelines, but has shown some activity. 36 However, objective response was rare, but most DTs were stabilised while they were progressive before treatment.
In conclusion, the main result of this study is the link between a specific type of surgery in FAP patients and the development of DTs. Regarding treatment efficacy, our disappointing results regarding medical treatment justifies the urgent need for randomised, prospective studies in FAP patients. In this setting, at least the prospective registration of treatments and results is required to improve the knowledge and management of FAP disease.
